How Real-World Data Is Shaping MS Treatment

Epstein–Barr virus (EBV) has become one of the most intensely studied topics in multiple sclerosis research. But how strong is the evidence linking EBV to MS, and could targeting the virus change the future of treatment and prevention? In this episode of the ECTRIMS Podcast, host ...  Show more

New Phase 3 data presented at the AAN conference 2026 provide compelling evidence that fenebrutinib may represent a high-efficacy oral treatment option for people living with relapsing multiple sclerosis. In this exclusive episode, leading experts Prof. Ludwig Kappos from Univers ...  Show more

Today I am speaking with Dr. Jin-Xiong She about all thing NAD+, we discuss what it is, how to measure your NAD+ levels, what impact your NAD+ levels have on your health and longevity, how to optimize your NAD+ levels and so much more!

<a href="https://www. ...

In this episode, Joe interviews Paul F. Daley, Ph.D., who worked with Sasha Shulgin in his lab for the last seven years of his life, helping him finish (and co-authoring) "The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds." He is now the co-founder, ...  Show more

The latest guidelines on disease-modifying treatment in multiple sclerosis (MS) from the Association of British Neurologists is discussed in this intercontinental podcast with perspectives from the UK, the USA, and Australia.   Participants: <ul> <li>Professor Alasdair Coles is H ...  Show more

In this episode of Better Thinking, Nesh Nikolic speaks with Lucette Cysique about the importance of understanding post-viral syndromes and how it can pave the way for enhanced long-term outcomes, benefiting both individuals and the wider community. Associate Professor Lucette Cy ...  Show more